Pasar al contenido principal

INVESTIGACION Y DESARROLLO DE INHIBIDORES SELECTIVOS BASADOS EN LA ESTRUCTURA DE ENZIMAS METABOLIZADORES DE ALDEHIDOS COMO DIANAS DE INTERES BIOTECNOLOGICO

PID2020-119424RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD AUTONOMA DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Targeting Retinaldehyde Dehydrogenases to Enhance Temozolomide Therapy in Glioblastoma

  • Jiménez, Rafael|||0000-0003-4103-8219
  • Constantinescu, Andrada
  • Yazir, Muhube
  • Alfonso Triguero, Paula|||0000-0002-6554-5656
  • Pequerul Pavón, Raquel|||0000-0002-0008-975X
  • Parés i Casasampera, Xavier|||0000-0002-5071-9465
  • Pérez-Alea, Mileidys|||0000-0002-8739-8087
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
  • Farrés, Jaume|||0000-0001-9069-3987
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
Glioblastoma (GB) is an aggressive malignant central nervous system tumor that is currently incurable. One of the main pitfalls of GB treatment is resistance to the chemotherapeutic standard of care, temozolomide (TMZ). The role of aldehyde dehydrogenases (ALDHs) in the glioma stem cell (GSC) subpopulation has been related to chemoresistance. ALDHs take part in processes such as cell proliferation, differentiation, invasiveness or metastasis and have been studied as pharmacological targets in cancer treatment. In the present work, three novel α,β-acetylenic amino thiolester compounds, with demonstrated efficacy as ALDH inhibitors, were tested in vitro on a panel of six human GB cell lines and one murine GB cell line. Firstly, the expression of the ALDH1A isoforms was assessed, and then inhibitors were tested for their cytotoxicity and their ability to inhibit cellular ALDH activity. Drug combination assays with TMZ were performed, as well as an assessment of the cell death mechanism and generation of ROS. A knockout of several ALDH genes was carried out in one of the human GB cell lines, allowing us to discuss their role in cell proliferation, migration capacity and resistance to treatment. Our results strongly suggest that ALDH inhibitors could be an interesting approach in the treatment of GB, with EC50 values in the order of micromolar, decreasing ALDH activity in GB cell lines to 40-50%.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Fluorescent substrates enable specific detection and structure-function insights into human aldehyde dehydrogenase isoforms

  • Pequerul Pavón, Raquel|||0000-0002-0008-975X
  • Covaleda Cortés, Daniela|||0009-0007-4919-0377
  • Sánchez-Vaca, Andrés S.|||0000-0002-7722-7161
  • Torres, Laura
  • Constantinescu, Andrada
  • Pérez-Alea, Mileidys|||0000-0002-8739-8087
  • Parés i Casasampera, Xavier|||0000-0002-5071-9465
  • Farrés, Jaume|||0000-0001-9069-3987
Aldehyde dehydrogenase (ALDH) isoforms are widely used as biomarkers and potential drug targets in cancer research. Quantitation of ALDH enzymatic activity in biological samples often relies on the use of commercially available assays that are quite unspecific and do not discriminate between the various ALDH isoforms. The availability of highly purified recombinant ALDH isoforms allowed us to perform a full kinetic characterization of ALDH isoforms with fluorogenic substrates, BODIPY™-aminoacetaldehyde (BAAA), the ALDEFLUOR™ assay reagent, and two naphthaldedyde derivatives, 6-methoxy-2-naphthaldehyde (MONAL-62) and 7-methoxy-1-naphthaldehyde (MONAL-71). All ALDH1A isoforms were active to different extend with BAAA, while ALDH3A1 did not show any activity. Remarkable kinetic differences between ALDH1A1, ALDH1A2, ALDH1A3, ALDH2 and ALDH3A1 were observed with naphthaldehyde derivatives. Exquisite sensitivity was attained with MONAL-62 with a lower detection limit of 2 amol or 10 molecules of enzyme per microliter for ALDH1A1. The high substrate specificity of ALDH1A1 for MONAL-71 provides an alternative assay for the unambiguous identification of this isoform. Enzymatic properties of isoforms were accounted for by in silico simulations of substrate docking to the active site of ALDH structures. In addition to substrate specificity, inhibitor selectivity of each isoform, as assessed by incubation with DIMATE and ABD0171 inhibitors, provided additional information about isoform composition in low-activity samples isolated from cell extracts. The method was successfully applied to the detection of ALDH isoform activity in triple-negative breast cancer cells.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Inter- and intra-tumoral ALDH1 heterogeneity in breast cancer identifies therapeutic opportunities for ALDH1A-specific inhibitors

  • Pequerul Pavón, Raquel|||0000-0002-0008-975X
  • Constantinescu, Andrada
  • Janji, Bassam
  • Kumar, Akinchan
  • Baier, Céline
  • Manosalva, Iris
  • Parés i Casasampera, Xavier|||0000-0002-5071-9465
  • Palacios, Òscar|||0000-0002-2987-7303
  • Spicuglia, Salvatore
  • Colignon, Delphine
  • Berrou, Axelle
  • Fournet, Guy
  • Berchard, Paul
  • Martin, Guillaume
  • Ceylan, Ismail|||0000-0002-7491-9269
  • Rebollido-Rios, Rocio|||0000-0002-8910-867X
  • Farrés, Jaume|||0000-0001-9069-3987
  • Pérez-Alea, Mileidys|||0000-0002-8739-8087
Basal-like breast cancer is an aggressive subtype with limited therapeutic options. Here, transcriptomic analysis of public datasets suggested distinct subtype- and cell-specific expression patterns of ALDH1A isoforms in breast tumors, with ALDH1A3 predominantly expressed in the epithelial cells of basal-like tumors, whereas ALDH1A2 and ALDH1A1 were enriched in stromal and immune-associated subpopulations. High expression of ALDH1A3 and ALDH1A2, but not ALDH1A1, is associated with poor prognosis in high-grade, lymph-node-positive tumors. To evaluate therapeutic targeting, we developed ABD0171, an irreversible, selective ALDH1A3 inhibitor with additional ALDH1A1 activity. ABD0171 disrupted key oncogenic pathways, including IL6/JAK/STAT3, tPA, and Src/FAK, resulting in robust antitumor and antimetastatic effects in vitro and in vivo, with a favorable safety profile. These findings establish ALDH1A3 as a therapeutic target in breast cancers with epithelial-basal traits and validate ABD0171 as a promising clinical candidate to address current treatment challenges.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Targeting Retinaldehyde Dehydrogenases to Enhance Temozolomide Therapy in Glioblastoma

  • Jiménez, Rafael
  • Constantinescu, Andrada
  • Yazir, Muhube
  • Alfonso Triguero, Paula
  • Pequerul, Raquel
  • Parés, Xavier
  • Pérez-Alea, Mileidys
  • Candiota, Ana Paula
  • Farrés, Jaume
  • Lorenzo, Julia
Glioblastoma (GB) is an aggressive malignant central nervous system tumor that is currently incurable. One of the main pitfalls of GB treatment is resistance to the chemotherapeutic standard of care, temozolomide (TMZ). The role of aldehyde dehydrogenases (ALDHs) in the glioma stem cell (GSC) subpopulation has been related to chemoresistance. ALDHs take part in processes such as cell proliferation, differentiation, invasiveness or metastasis and have been studied as pharmacological targets in cancer treatment. In the present work, three novel α,β-acetylenic amino thiolester compounds, with demonstrated efficacy as ALDH inhibitors, were tested in vitro on a panel of six human GB cell lines and one murine GB cell line. Firstly, the expression of the ALDH1A isoforms was assessed, and then inhibitors were tested for their cytotoxicity and their ability to inhibit cellular ALDH activity. Drug combination assays with TMZ were performed, as well as an assessment of the cell death mechanism and generation of ROS. A knockout of several ALDH genes was carried out in one of the human GB cell lines, allowing us to discuss their role in cell proliferation, migration capacity and resistance to treatment. Our results strongly suggest that ALDH inhibitors could be an interesting approach in the treatment of GB, with EC50 values in the order of micromolar, decreasing ALDH activity in GB cell lines to 40–50%., This research was funded by the Spanish Ministerio de Ciencia e Innovación (Agencia Estatal de Investigación, grant numbers PID2020-119424RB-I00, PID2020-113058GB-I00, PID2021-127983OB-C22/AEI/10.13039/501100011033). This research was also supported by Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR, grup consolidat N-TETRASCAN 2021SGR00135). R.P. obtained financial support from the company Advanced BioDesign through a research contract agreement with Universitat Autònoma de Barcelona. This work was also supported by Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN [https://www.ciber-bbn.es/en, accessed on 26 August 2024], CB06/01/0010), an initiative of the Instituto de Salud Carlos III (Spain). R.J. was a recipient of a PIF predoctoral fellowship from Universitat Autònoma de Barcelona., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Design, synthesis, biological evaluation and in silico study of benzyloxybenzaldehyde derivatives as selective aldh1a3 inhibitors

  • Ibrahim, Ali I. M.|||0000-0002-8668-4647
  • Ikhmais, Balqis
  • Batlle, Elisabet
  • Abuharb, Waed K.
  • Jha, Vibhu|||0000-0002-1168-7480
  • Jaradat, Khaled T.|||0000-0002-0148-4022
  • Jiménez, Rafael|||0000-0003-4103-8219
  • Pequerul Pavón, Raquel|||0000-0002-0008-975X
  • Parés i Casasampera, Xavier|||0000-0002-5071-9465
  • Farrés, Jaume|||0000-0001-9069-3987
  • Pors, Klaus|||0000-0002-0837-5208
Aldehyde dehydrogenase 1A3 (ALDH1A3) has recently gained attention from researchers in the cancer field. Several studies have reported ALDH1A3 overexpression in different cancer types, which has been found to correlate with poor treatment recovery. Therefore, finding selective inhibitors against ALDH1A3 could result in new treatment options for cancer treatment. In this study, ALDH1A3-selective candidates were designed based on the physiological substrate resemblance, synthesized and investigated for ALDH1A1, ALDH1A3 and ALDH3A1 selectivity and cytotoxicity using ALDH-positive A549 and ALDH-negative H1299 cells. Two compounds (ABMM- 15 and ABMM-16), with a benzyloxybenzaldehyde scaffold, were found to be the most potent and selective inhibitors for ALDH1A3, with IC50 values of 0.23 and 1.29 μM, respectively. The results also show no significant cytotoxicity for ABMM-15 and ABMM-16 on either cell line. However, a few other candidates (ABMM-6, ABMM-24, ABMM-32) showed considerable cytotoxicity on H1299 cells, when compared to A549 cells, with IC50 values of 14.0, 13.7 and 13.0μM, respectively. The computational study supported the experimental results and suggested a good binding for ABMM- 15 and ABMM-16 to the ALDH1A3 isoform. From the obtained results, it can be concluded that benzyloxybenzaldehyde might be considered a promising scaffold for further drug discovery aimed at exploiting ALDH1A3 for therapeutic intervention.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Perspective on the structural basis for human aldo-keto reductase 1b10 inhibition

  • Ruiz, Francesc Xavier|||0000-0002-0457-0030
  • Parés i Casasampera, Xavier|||0000-0002-5071-9465
  • Farrés, Jaume|||0000-0001-9069-3987
Human aldo-keto reductase 1B10 (AKR1B10) is overexpressed in many cancer types and is involved in chemoresistance. This makes AKR1B10 to be an interesting drug target and thus many enzyme inhibitors have been investigated. High-resolution crystallographic structures of AKR1B10 with various reversible inhibitors were deeply analyzed and compared to those of analogous complexes with aldose reductase (AR). In both enzymes, the active site included an anion-binding pocket and, in some cases, inhibitor binding caused the opening of a transient specificity pocket. Different structural conformers were revealed upon inhibitor binding, emphasizing the importance of the highly variable loops, which participate in the transient opening of additional binding subpockets. Two key differences between AKR1B10 and AR were observed regarding the role of external loops in inhibitor binding. The first corresponded to the alternative conformation of Trp112 (Trp111 in AR). The second difference dealt with loop A mobility, which defined a larger and more loosely packed subpocket in AKR1B10. From this analysis, the general features that a selective AKR1B10 inhibitor should comply with are the following: an anchoring moiety to the anion-binding pocket, keeping Trp112 in its native conformation (AKR1B10-like), and not opening the specificity pocket in AR.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Expansion of the 4-(Diethylamino)benzaldehyde Scaffold to Explore the Impact on Aldehyde Dehydrogenase Activity and Antiproliferative Activity in Prostate Cancer

  • Ibrahim, Ali I. M.|||0000-0002-8668-4647
  • Batlle, Elisabet
  • Sneha, Smarakan
  • Jiménez, Rafael|||0000-0003-4103-8219
  • Pequerul Pavón, Raquel|||0000-0002-0008-975X
  • Parés i Casasampera, Xavier|||0000-0002-5071-9465
  • Rüngeler, Till
  • Jha, Vibhu|||0000-0002-1168-7480
  • Tuccinardi, Tiziano|||0000-0002-6205-4069
  • Sadiq, Maria
  • Frame, Fiona
  • Maitland, Norman J.
  • Farrés, Jaume|||0000-0001-9069-3987
  • Pors, Klaus|||0000-0002-0837-5208
Aldehyde dehydrogenases (ALDHs) are overexpressed in various tumor types including prostate cancer and considered a potential target for therapeutic intervention. 4-(Diethylamino)benzaldehyde (DEAB) has been extensively reported as a pan-inhibitor of ALDH isoforms, and here, we report on the synthesis, ALDH isoform selectivity, and cellular potencies in prostate cancer cells of 40 DEAB analogues; three analogues (14, 15, and 16) showed potent inhibitory activity against ALDH1A3, and two analogues (18 and 19) showed potent inhibitory activity against ALDH3A1. Significantly, 16 analogues displayed increased cytotoxicity (IC = 10-200 μM) compared with DEAB (>200 μM) against three different prostate cancer cell lines. Analogues 14 and 18 were more potent than DEAB against patient-derived primary prostate tumor epithelial cells, as single agents or in combination treatment with docetaxel. In conclusion, our study supports the use of DEAB as an ALDH inhibitor but also reveals closely related analogues with increased selectivity and potency.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Structural and biochemical evidence that ATP inhibits the cancer biomarker human aldehyde dehydrogenase 1A3

  • Castellví Toledo, Albert|||0000-0002-1814-1210
  • Pequerul Pavón, Raquel|||0000-0002-0008-975X
  • Barracco, Vito
  • Juanhuix, Judith|||0000-0003-3728-8215
  • Parés i Casasampera, Xavier|||0000-0002-5071-9465
  • Farrés, Jaume|||0000-0001-9069-3987
Human aldehyde dehydrogenase (ALDH) participates in the oxidative stress response and retinoid metabolism, being involved in several diseases, including cancer, diabetes and obesity. The ALDH1A3 isoform has recently elicited wide interest because of its potential use as a cancer stem cell biomarker and drug target. We report high-resolution three-dimensional ALDH1A3 structures for the apo-enzyme, the NAD+ complex and a binary complex with ATP. Each subunit of the ALDH1A3-ATP complex contains one ATP molecule bound to the adenosine-binding pocket of the cofactor-binding site. The ATP complex also shows a molecule, putatively identified as a polyethylene glycol aldehyde, covalently bound to the active-site cysteine. This mimics the thioacyl-enzyme catalytic intermediate, which is trapped in a dead enzyme lacking an active cofactor. At physiological concentrations, ATP inhibits the dehydrogenase activity of ALDH1A3 and other isoforms, with a Ki value of 0.48 mM for ALDH1A3, showing a mixed inhibition type against NAD+. ATP also inhibits esterase activity in a concentration-dependent manner. The current ALDH1A3 structures at higher resolution will facilitate the rational design of potent and selective inhibitors. ATP binding to ALDH1A3 enables activity modulation by the energy status of the cell and metabolic reprogramming, which may be relevant in several disease conditions.